Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Alterity Therapeutics Limited (ASX:ATHE) is an Australian biotechnology company founded in 1997 and headquartered in Melbourne. Originally incorporated as Prana Biotechnology Limited, the company rebranded to its current name in April 2019. Alterity focuses on developing therapeutic drugs to treat neurodegenerative diseases, particularly Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. As a clinical-stage biotechnology company, Alterity has been publicly traded since 2003 and represents the emerging field of precision medicine targeting neurodegeneration through novel therapeutic approaches.
Latest newsMore news →
Alterity Therapeutics announced the granting of a new U.S. composition of matter patent for its drug candidate ATH434, extending protection to at least 2045.39d agoAlterity Therapeutics received FDA End-of-Phase 2 meeting minutes confirming the registrational pathway for ATH434 in Multiple System Atrophy.75d agoAlterity Therapeutics achieved alignment with the U.S. FDA on the pivotal Phase 3 program for ATH434 in Multiple System Atrophy.103d ago